WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100950
CAS#: 165800-06-6 (hydrate)
Description: Zoledronic acid is a synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover.
MedKoo Cat#: 100950
Name: Zoledronic acid
CAS#: 165800-06-6 (hydrate)
Chemical Formula: C5H12N2O8P2
Exact Mass: 271.99632
Molecular Weight: 290.1
Elemental Analysis: C, 22.07; H, 3.70; N, 10.30; O, 41.16; P, 22.77
Related CAS #: 165800-06-6 (hydrate) 118072-93-8 (anhydrous)
Synonym: Zoledronic acid; CGP 42446; CGP42446A; ZOL 446; zoledronate; zoledronate. brand name: Zometa; Reclast.
IUPAC/Chemical Name: (1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid hydrate
InChi Key: FUXFIVRTGHOMSO-UHFFFAOYSA-N
InChi Code: InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
SMILES Code: OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1.[H]O[H]
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 290.1 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Albani-Campanario M, BuendÃa-DÃaz G, Flores-Islas Mde L, Maquita-Nakano C, Ochoa-Cervantes J. [Zoledronic acid-based uveitis: a case report and a bibliography review]. Ginecol Obstet Mex. 2012 May;80(5):355-9. Review. Spanish. PubMed PMID: 23301428.
2: Huang WW, Huang C, Liu J, Zheng HY, Lin L. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2012;7(7):e40783. doi: 10.1371/journal.pone.0040783. Epub 2012 Jul 26. Review. PubMed PMID: 22844410; PubMed Central PMCID: PMC3406041.
3: Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, Chen DC, Hai-Bin X. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7. Review. PubMed PMID: 22805729.
4: Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol. 2012 Nov;23(11):2782-90. doi: 10.1093/annonc/mds169. Epub 2012 Jun 22. Review. PubMed PMID: 22730099; PubMed Central PMCID: PMC3477882.
5: Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):425-37. doi: 10.1586/erp.12.31. Epub 2012 Apr 27. Review. PubMed PMID: 22540167.
6: Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer. 2012 Jul;20(7):1353-60. doi: 10.1007/s00520-012-1461-4. Epub 2012 Apr 27. Review. PubMed PMID: 22539050; PubMed Central PMCID: PMC3360851.
7: Gnant M. Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep. 2012 Feb;14(1):35-43. doi: 10.1007/s11912-011-0209-5. Review. PubMed PMID: 22113793.
8: Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer. 2012 Jan;48(2):187-95. doi: 10.1016/j.ejca.2011.10.021. Epub 2011 Nov 17. Review. PubMed PMID: 22100904.
9: Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011 Oct;29(8):533-41. doi: 10.3109/07357907.2011.605413. Epub 2011 Aug 15. Review. PubMed PMID: 21843051.
10: Lipton A. Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther. 2011 Jul;11(7):999-1012. doi: 10.1586/era.11.71. Review. PubMed PMID: 21806323.